Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mankind Pharma's share price for the quarter that ended in Mar. 2026 was ₹2005.85. Mankind Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 413 Mil. Therefore, Mankind Pharma's market cap for the quarter that ended in Mar. 2026 was ₹828,071 Mil.
Mankind Pharma's quarterly market cap
declined
from Sep. 2025 (₹1,005,871 Mil) to Dec. 2025 (₹906,664 Mil) and
declined
from Dec. 2025 (₹906,664 Mil) to Mar. 2026 (₹828,071 Mil).
Mankind Pharma's annual market cap
increased
from Mar. 2024 (₹920,291 Mil) to Mar. 2025 (₹999,741 Mil) but then
declined
from Mar. 2025 (₹999,741 Mil) to Mar. 2026 (₹828,071 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mankind Pharma's Enterprise Value for Today is ₹1,072,723 Mil.
Mankind Pharma (BOM:543904) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Mankind Pharma Market Cap Related Terms
Mankind Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mankind Pharma's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mankind Pharma (BOM:543904) has a Market Cap of ₹1,028,959 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mankind Pharma and its competitors. According to the industry distribution chart, Mankind Pharma ranks #51 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Mankind Pharma's Market Cap too high?
Mankind Pharma's current Market Cap is ₹1,028,959 Mil. Based on the distribution chart, Mankind Pharma ranks #51 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mankind Pharma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #51 out of 1023 companies for Market Cap. This places Mankind Pharma in the top 5% of its industry — outperforming the majority of peers. The industry median Market Cap is 216.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 216.46, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median Market Cap is 216.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current Market Cap is ₹1,028,959 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,934.91, compared to a current price of ₹2,491.45 — trading 15.1% below its estimated fair value. The current Market Cap is ₹1,028,959 Mil. Mankind Pharma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current Market Cap is ₹1,028,959 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,491.45 is trading 15.1% below its estimated GF Value™ of ₹2,934.91.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
Market Cap: ₹1,028,959 Mil
GF Value™: ₹2,934.91 vs. price of ₹2,491.45 (15.1% below fair value)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
90GF Score
Get the complete analysis for BOM:543904
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
